3 Stocks Dragging The Drugs Industry Downward

TheStreet highlights 3 stocks pushing the drugs industry lower today.
By TheStreet Wire ,

Two out of the three major indices are trading lower today with the

Dow Jones Industrial Average

(

^DJI

) trading down 6 points (0.0%) at 17,753 as of Wednesday, Nov. 11, 2015, 11:55 AM ET. The NYSE advances/declines ratio sits at 1,244 issues advancing vs. 1,682 declining with 165 unchanged.

The Drugs industry currently sits down 0.9% versus the S&P 500, which is down 0.1%. On the negative front, top decliners within the industry include

Intercept Pharmaceuticals

(

ICPT

), down 7.9%,

Mallinckrodt

(

MNK

), down 3.7%,

Valeant Pharmaceuticals International

(

VRX

), down 3.1%,

Incyte

(

INCY

), down 2.5% and

AbbVie

(

ABBV

), down 2.1%. Top gainers within the industry include

Endo International

(

ENDP

), up 3.2%,

Allergan

(

AGN

), up 1.0%,

Eli Lilly and

(

LLY

), up 0.8%,

Shire

(

SHPG

), up 0.6% and

Johnson & Johnson

(

JNJ

), up 0.6%.

TheStreet would like to highlight 3 stocks pushing the industry lower today:

3.

Horizon Pharma

(

HZNP

) is one of the companies pushing the Drugs industry lower today. As of noon trading, Horizon Pharma is down $4.50 (-20.1%) to $17.88 on heavy volume. Thus far, 13.0 million shares of Horizon Pharma exchanged hands as compared to its average daily volume of 6.4 million shares. The stock has ranged in price between $17.55-$19.61 after having opened the day at $19.00 as compared to the previous trading day's close of $22.38.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Horizon Pharma plc, a specialty biopharmaceutical company, engages in identifying, developing, acquiring or in-licensing, and commercializing medicines for the treatment of arthritis, pain, inflammatory, and/or orphan diseases in the United States and internationally. Horizon Pharma has a market cap of $3.6 billion and is part of the health care sector. Shares are up 73.6% year-to-date as of the close of trading on Tuesday. Currently there are 6 analysts that rate Horizon Pharma a buy, no analysts rate it a sell, and 1 rates it a hold.

TheStreet Ratings rates

Horizon Pharma

as a

sell

. The area that we feel has been the company's primary weakness has been its disappointing return on equity. Get the full

Horizon Pharma Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

2. As of noon trading,

Celgene

(

CELG

) is down $0.64 (-0.6%) to $113.13 on light volume. Thus far, 1.2 million shares of Celgene exchanged hands as compared to its average daily volume of 5.7 million shares. The stock has ranged in price between $112.79-$114.28 after having opened the day at $114.10 as compared to the previous trading day's close of $113.77.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases in the United States and Internationally. Celgene has a market cap of $89.6 billion and is part of the health care sector. Shares are up 1.7% year-to-date as of the close of trading on Tuesday. Currently there are 13 analysts that rate Celgene a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates

Celgene

as a

buy

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, notable return on equity, expanding profit margins and solid stock price performance. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full

Celgene Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

1. As of noon trading,

Merck

(

MRK

) is down $0.39 (-0.7%) to $54.04 on light volume. Thus far, 2.6 million shares of Merck exchanged hands as compared to its average daily volume of 13.8 million shares. The stock has ranged in price between $54.00-$55.00 after having opened the day at $54.81 as compared to the previous trading day's close of $54.43.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Merck & Co., Inc. provides health care solutions worldwide. Merck has a market cap of $151.5 billion and is part of the health care sector. Shares are down 4.2% year-to-date as of the close of trading on Tuesday. Currently there are 7 analysts that rate Merck a buy, no analysts rate it a sell, and 7 rate it a hold.

TheStreet Ratings rates

Merck

as a

buy

. The company's strengths can be seen in multiple areas, such as its compelling growth in net income, impressive record of earnings per share growth and expanding profit margins. We feel its strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full

Merck Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF

(

XPH

) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech

(

BIS

).

Loading ...